FTC Issues Second Request To Watson, Andrx

Law360, New York (May 3, 2006, 12:00 AM EDT) -- The proposed marriage of generic drug makers Watson Pharmaceuticals Inc. and Andrx Corp. has drawn new attention from the Federal Trade Commission, which issued a second request for information in order to study possible antitrust concerns.

The agency has plenty of details to crunch, given the multiple overlapping drugs manufactured by the companies, which hope to merge after Watson announced in March its plans to purchase Andrx for $1.9 billion.

Although only about 3% of proposed corporate mergers lead to second requests for information from the...
To view the full article, register now.